• Aswathy S S
• Rupitha N S
• Sanitha M
• Savitha Mol G M
• Anusha Jasmin R J

Inflammation has always been thought of as detrimental in the pathophysiology of multiple sclerosis (MS). However, emerging genetic data, magnetic-resonance-imaging studies, and immunopathological evidence challenge this simplistic view. The evidence leads to the conclusion that inflammation is tightly regulated, and that its net effect may be beneficial in MS, thus explaining some of the results from recent trials of anti-inflammatory agents. The use of anti-inflammatory drugs to treat MS may not be appropriate in all cases. Corticosteroids, such as oral prednisone and intravenous methylprednisolone, are prescribed to reduce nerve inflammation. In multiple sclerosis, an abnormal immune system attacks healthy nerve cells, causing inflammation and lesions in the brain and spine. The immune system primarily attacks myelin, a fatty substance that insulates nerve fibers (axons) and helps in the conduction of electrical signals.

methylprednisolone, dexamethasone and prednisone

"AN INSILICO EVALUATION OF ANTI INFLAMMATORY DRUGS -IN MULTIPLE SCLEROSIS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.10, Issue 9, page no.d753-d759, September-2023, Available :http://www.jetir.org/papers/JETIR2309382.pdf

"AN INSILICO EVALUATION OF ANTI INFLAMMATORY DRUGS -IN MULTIPLE SCLEROSIS", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.10, Issue 9, page no. ppd753-d759, September-2023, Available at : http://www.jetir.org/papers/JETIR2309382.pdf